NASDAQ:VSTM - Verastem Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.16 +0.14 (+2.79 %)
(As of 05/22/2018 08:03 AM ET)
Previous Close$5.02
Today's Range$5.11 - $5.28
52-Week Range$1.92 - $5.71
Volume2.05 million shs
Average Volume1.38 million shs
Market Capitalization$287.68 million
P/E Ratio-2.93
Dividend YieldN/A
Beta2.18

About Verastem (NASDAQ:VSTM)

Verastem logoVerastem, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K) signaling pathways. The company's lead FAK inhibitor is defactinib, an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. Its defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. The company also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with hematologic cancers through the dual inhibition of PI3K delta and gamma. Its duvelisib is in Phase 3 randomized and late-and mid-stage clinical trials for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with double-refractory indolent non-Hodgkin lymphoma. The company has license agreements with Infinity Pharmaceuticals, Inc.; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is headquartered in Needham, Massachusetts.

Receive VSTM News and Ratings via Email

Sign-up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:VSTM
CUSIP92337C10
Phone781-292-4200

Debt

Debt-to-Equity Ratio0.39
Current Ratio4.45
Quick Ratio4.45

Price-To-Earnings

Trailing P/E Ratio-2.93
Forward P/E Ratio-3.51
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.19 per share
Price / Book4.34

Profitability

EPS (Most Recent Fiscal Year)($1.76)
Net Income$-67,800,000.00
Net MarginsN/A
Return on Equity-163.60%
Return on Assets-107.14%

Miscellaneous

Employees69
Outstanding Shares57,310,000

Verastem (NASDAQ:VSTM) Frequently Asked Questions

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

How were Verastem's earnings last quarter?

Verastem Inc (NASDAQ:VSTM) issued its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.02. View Verastem's Earnings History.

When is Verastem's next earnings date?

Verastem is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Verastem.

What price target have analysts set for VSTM?

9 Wall Street analysts have issued twelve-month price objectives for Verastem's shares. Their forecasts range from $1.50 to $17.00. On average, they anticipate Verastem's share price to reach $12.1875 in the next year. View Analyst Ratings for Verastem.

What are Wall Street analysts saying about Verastem stock?

Here are some recent quotes from research analysts about Verastem stock:
  • 1. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Our Takeaways From Verastem Investor Day; Reiterate Buy We anticipate duvelisib approval in 4Q18. On May 2, Verastem Oncology held an Analyst and Investor Day in New York and provided an overview on duvelisib’s development and management’s plans for the drug’s commercial launch. Recall, on February 7, Verastem filed a NDA application for duvelisib, the company’s dual PI3K-γ/δ inhibitor, for the treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (r/r CLL/ SLL). The company has also filed for an accelerated approval of duvelisib for the treatment of follicular lymphoma (FL). We note that the FDA has granted a priority review for the duvelisib application, with the PDUFA date scheduled for October 5." (5/3/2018)
  • 2. According to Zacks Investment Research, "Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. " (3/20/2018)
  • 3. Cantor Fitzgerald analysts commented, "Working off Overhangs. We think VSTM shares are undervalued relative to the duvelisib opportunity, and this is partly a function, in our view, of overhangs, particularly cash. VSTM had just under $87 mln in cash, which is sufficient to fund the company into 2H18, but will need additional capital to see duvelisib through commercialization. VSTM has an additional $35 mln available under a debt facility, and the company could add additional cash through a partner deal. It has been our anticipation that VSTM will need to address the capital markets in some way in 2018." (3/13/2018)
  • 4. Cann analysts commented, "Verastem announced today that a poster highlighting the synergistic effects of Duvelisib in combination with immune checkpoint or co-stimulatory antibodies in preclinical models of B cell lymphoma was presented at ASCO-SITC Clinical Immuno- Oncology Symposium. The purpose of this study was to evaluate whether Duvelisib therapy could augment the efficacy of immune checkpoint inhibitors or co-stimulatory agents in the A20 mouse model of B cell lymphoma. Verastem reported that as a result of beneficial changes within the tumor microenvironment, it observed enhancement by Duvelisib of the anti-tumor efficacy of immune checkpoint or co-stimulatory antibodies in this preclinical B cell lymphoma model." (1/26/2018)

Who are some of Verastem's key competitors?

Who are Verastem's key executives?

Verastem's management team includes the folowing people:
  • Mr. Robert Forrester, Chief Exec. Officer, Pres and Director (Age 54)
  • Ms. Julie B. Feder, Chief Financial Officer
  • Dr. NgocDiep T Le M.D., Ph.D., Chief Medical Officer
  • Mr. Richard H. Aldrich, Founder and Consultant (Age 64)
  • Dr. Robert A. Weinberg, Co-Founder and Chair of Scientific Advisory Board

Has Verastem been receiving favorable news coverage?

Media coverage about VSTM stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Verastem earned a media sentiment score of 0.20 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.55 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Verastem's major shareholders?

Verastem's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (5.37%), BlackRock Inc. (1.84%), Dimensional Fund Advisors LP (0.96%), Millennium Management LLC (0.53%), GSA Capital Partners LLP (0.49%) and Victory Capital Management Inc. (0.54%). Company insiders that own Verastem stock include Michael Kauffman and Timothy J Barberich. View Institutional Ownership Trends for Verastem.

Which institutional investors are selling Verastem stock?

VSTM stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Millennium Management LLC, Royal Bank of Canada and UBS Group AG. View Insider Buying and Selling for Verastem.

Which institutional investors are buying Verastem stock?

VSTM stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, Victory Capital Management Inc., GSA Capital Partners LLP, BlackRock Inc., Alambic Investment Management L.P., Element Capital Management LLC, ClariVest Asset Management LLC and Northern Trust Corp. View Insider Buying and Selling for Verastem.

How do I buy shares of Verastem?

Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $5.16.

How big of a company is Verastem?

Verastem has a market capitalization of $287.68 million. The biopharmaceutical company earns $-67,800,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Verastem employs 69 workers across the globe.

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected]


MarketBeat Community Rating for Verastem (VSTM)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  288 (Vote Outperform)
Underperform Votes:  176 (Vote Underperform)
Total Votes:  464
MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote "Outperform" if you believe VSTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSTM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Verastem (NASDAQ:VSTM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Verastem in the last 12 months. Their average twelve-month price target is $12.1875, suggesting that the stock has a possible upside of 136.19%. The high price target for VSTM is $17.00 and the low price target for VSTM is $1.50. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.892.882.882.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.1875$11.6429$10.3571$7.75
Price Target Upside: 136.19% upside241.43% upside194.24% upside134.85% upside

Verastem (NASDAQ:VSTM) Consensus Price Target History

Price Target History for Verastem (NASDAQ:VSTM)

Verastem (NASDAQ:VSTM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018B. RileySet Price TargetBuy$17.00LowView Rating Details
5/3/2018HC WainwrightReiterated RatingBuy$10.00HighView Rating Details
5/2/2018Cantor FitzgeraldSet Price TargetBuy$17.00HighView Rating Details
5/2/2018Seaport Global SecuritiesInitiated CoverageBuy ➝ Buy$14.00LowView Rating Details
1/26/2018CannReiterated RatingBuy$13.00LowView Rating Details
12/21/2017OppenheimerSet Price TargetBuy$13.00MediumView Rating Details
12/11/2017Raymond JamesReiterated RatingBuyHighView Rating Details
12/1/2017Roth CapitalInitiated CoverageBuy$12.00HighView Rating Details
6/28/2017Jefferies GroupReiterated RatingHold$1.50HighView Rating Details
4/13/2017CIBCReiterated RatingOutperform ➝ Outperform$6.00HighView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Verastem (NASDAQ:VSTM) Earnings History and Estimates Chart

Earnings by Quarter for Verastem (NASDAQ:VSTM)

Verastem (NASDAQ:VSTM) Earnings Estimates

2018 EPS Consensus Estimate: ($1.59)
2019 EPS Consensus Estimate: ($1.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.47)($0.37)($0.41)
Q2 20183($0.41)($0.37)($0.39)
Q3 20183($0.49)($0.29)($0.39)
Q4 20183($0.59)($0.19)($0.40)
Q1 20191($0.53)($0.53)($0.53)
Q2 20191($0.19)($0.19)($0.19)
Q3 20191($0.20)($0.20)($0.20)
Q4 20191($0.21)($0.21)($0.21)

Verastem (NASDAQ VSTM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.40)N/AView Earnings Details
5/8/2018Q1 2018($0.39)($0.41)ViewN/AView Earnings Details
3/13/2018Q4 2017($0.4210)($0.4330)ViewN/AView Earnings Details
11/7/2017Q3 2017($0.32)($0.61)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.34)($0.36)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.3520)($0.35)ViewN/AView Earnings Details
3/23/2017Q4 2016($0.27)($0.32)ViewN/AView Earnings Details
11/7/2016Q3($0.24)($0.21)ViewN/AView Earnings Details
8/8/2016Q2($0.29)($0.23)ViewN/AView Earnings Details
5/9/2016($0.30)($0.22)ViewN/AView Earnings Details
3/3/2016Q415($0.36)($0.32)ViewListenView Earnings Details
11/9/2015Q3 2015($0.43)($0.42)ViewN/AView Earnings Details
8/10/2015Q2($0.45)($0.42)ViewN/AView Earnings Details
5/11/2015Q1($0.41)($0.46)ViewN/AView Earnings Details
3/10/2015($0.54)($0.53)ViewN/AView Earnings Details
10/30/2014($0.51)($0.52)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.52)($0.51)ViewN/AView Earnings Details
5/8/2014($0.43)($0.51)ViewN/AView Earnings Details
3/6/2014Q4($0.47)($0.45)ViewListenView Earnings Details
11/12/2013Q3($0.4420)($0.47)ViewN/AView Earnings Details
8/13/2013Q2 2013($0.41)($0.49)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.43)($0.44)ViewN/AView Earnings Details
3/27/2013Q4 2012($0.40)($0.39)ViewN/AView Earnings Details
11/13/2012Q3 2012($0.36)($0.51)ViewN/AView Earnings Details
8/13/2012Q2 2012($0.34)($0.34)ViewN/AView Earnings Details
5/14/2012Q1 2012($0.28)($0.47)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Verastem (NASDAQ:VSTM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Verastem (NASDAQ VSTM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.06%
Institutional Ownership Percentage: 25.96%
Insider Trading History for Verastem (NASDAQ:VSTM)
Institutional Ownership by Quarter for Verastem (NASDAQ:VSTM)

Verastem (NASDAQ VSTM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/5/2017Timothy J BarberichDirectorBuy60,538$3.95$239,125.10130,000View SEC Filing  
5/15/2017Timothy J BarberichDirectorBuy30,000$2.45$73,500.0069,462View SEC Filing  
6/29/2015Monica SinghGeneral CounselBuy1,000$6.95$6,950.00View SEC Filing  
6/29/2015Robert ForresterCEOBuy2,000$7.11$14,220.00View SEC Filing  
6/18/2015Dan PatersonCOOBuy1,000$8.05$8,050.00View SEC Filing  
6/17/2015Robert ForresterCEOBuy1,000$7.97$7,970.00View SEC Filing  
1/28/2015Christoph H WestphalChairmanBuy1,230,769$6.50$7,999,998.50View SEC Filing  
1/28/2015Timothy J BarberichDirectorBuy38,462$6.50$250,003.00View SEC Filing  
12/29/2014Joanna HorobinInsiderBuy750$8.60$6,450.00View SEC Filing  
12/29/2014S. Louise PhanstielDirectorBuy10,000$8.54$85,400.00View SEC Filing  
12/26/2014Stephen A SherwinDirectorBuy2,500$8.56$21,400.00View SEC Filing  
12/24/2014Paul A FriedmanDirectorBuy3,000$8.31$24,930.00View SEC Filing  
12/23/2014Henri A TermeerDirectorBuy19,100$8.09$154,519.00View SEC Filing  
12/23/2014Monica SinghGeneral CounselBuy1,000$8.09$8,090.00View SEC Filing  
12/19/2014Christoph H WestphalChairmanBuy1,500$8.50$12,750.00View SEC Filing  
12/19/2014Dan PatersonCOOBuy2,000$8.52$17,040.00View SEC Filing  
12/19/2014Robert ForresterCEOBuy1,000$8.66$8,660.00View SEC Filing  
11/11/2014Alison Frances LawtonDirectorBuy2,500$9.17$22,925.00View SEC Filing  
9/17/2014Michael KauffmanDirectorBuy3,000$9.10$27,300.00View SEC Filing  
5/30/2014Timothy J BarberichDirectorBuy1,000$9.90$9,900.00View SEC Filing  
5/20/2014Richard AldrichDirectorBuy1,000$8.37$8,370.00408,142View SEC Filing  
5/15/2014Dan PatersonInsiderBuy1,000$7.47$7,470.0058,143View SEC Filing  
5/14/2014Christoph WestphalChairmanBuy2,000$7.56$15,120.00700,264View SEC Filing  
5/13/2014Robert ForresterCEOBuy1,000$7.62$7,620.00239,320View SEC Filing  
11/18/2013Christoph WestphalDirectorBuy1,000$9.60$9,600.00696,872View SEC Filing  
11/11/2013Richard AldrichDirectorBuy1,000$10.93$10,930.00407,142View SEC Filing  
11/4/2013Richard AldrichDirectorBuy1,000$10.51$10,510.00View SEC Filing  
10/28/2013Richard AldrichDirectorBuy1,000$11.26$11,260.00View SEC Filing  
10/21/2013Richard AldrichDirectorBuy1,000$12.57$12,570.00View SEC Filing  
10/14/2013Richard AldrichDirectorBuy1,000$10.56$10,560.00407,142View SEC Filing  
10/7/2013Richard AldrichDirectorBuy1,000$11.53$11,530.00407,142View SEC Filing  
9/30/2013Richard AldrichDirectorBuy1,000$12.55$12,550.00407,142View SEC Filing  
9/23/2013Richard AldrichDirectorBuy1,000$13.17$13,170.00407,142View SEC Filing  
9/16/2013Richard AldrichDirectorBuy1,000$13.81$13,810.00407,142View SEC Filing  
9/9/2013Richard AldrichDirectorBuy1,000$14.04$14,040.00View SEC Filing  
9/3/2013Richard AldrichDirectorBuy1,000$14.07$14,070.00407,142View SEC Filing  
8/26/2013Richard AldrichDirectorBuy1,000$14.21$14,210.00407,142View SEC Filing  
8/19/2013Richard AldrichDirectorBuy1,000$13.45$13,450.00407,142View SEC Filing  
8/12/2013Richard AldrichDirectorBuy1,000$14.75$14,750.00407,142View SEC Filing  
8/5/2013Richard AldrichDirectorBuy1,000$15.25$15,250.00407,142View SEC Filing  
7/29/2013Richard AldrichDirectorBuy1,000$15.15$15,150.00View SEC Filing  
7/24/2013Richard AldrichDirectorBuy1,000$16.39$16,390.00View SEC Filing  
7/15/2013Richard AldrichDirectorBuy1,000$17.19$17,190.00View SEC Filing  
7/8/2013Richard AldrichDirectorBuy1,000$14.69$14,690.00View SEC Filing  
7/1/2013Richard AldrichDirectorBuy1,000$14.11$14,110.00View SEC Filing  
6/13/2013Robert ForresterCOOBuy1,000$11.39$11,390.00View SEC Filing  
6/12/2013Henri A TermeerDirectorBuy5,823$9.74$56,716.02View SEC Filing  
6/12/2013Lp Chp IIIMajor ShareholderBuy48,171$9.40$452,807.40View SEC Filing  
6/11/2013S. Louise PhanstielDirectorBuy12,000$9.30$111,600.00View SEC Filing  
6/7/2013Christoph H WestphalCEOBuy1,000$9.06$9,060.00View SEC Filing  
5/13/2013John K ClarkeDirectorBuy25,000$9.74$243,500.00View SEC Filing  
5/1/2013John K ClarkeDirectorBuy10,000$9.66$96,600.00View SEC Filing  
4/17/2013John K ClarkeDirectorBuy5,631$9.50$53,494.50View SEC Filing  
12/18/2012Lp Chp IIIMajor ShareholderBuy6,193$7.87$48,738.91View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Verastem (NASDAQ VSTM) News Headlines

Source:
DateHeadline
Verastem Oncology to Present Scientific Data Supporting Immuno-Oncology Applications of Duvelisib & Defactinib at ...Verastem Oncology to Present Scientific Data Supporting Immuno-Oncology Applications of Duvelisib & Defactinib at ...
www.businesswire.com - May 21 at 5:09 PM
Verastem Oncology to Present Scientific Data Supporting Immuno-Oncology Applications of Duvelisib & Defactinib at the 3rd Annual Advances in Immuno-Oncology CongressVerastem Oncology to Present Scientific Data Supporting Immuno-Oncology Applications of Duvelisib & Defactinib at the 3rd Annual Advances in Immuno-Oncology Congress
finance.yahoo.com - May 21 at 5:09 PM
Verastem Inc (VSTM) Receives Consensus Recommendation of "Buy" from AnalystsVerastem Inc (VSTM) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 21 at 5:32 AM
26 Stocks Moving In Wednesdays Pre-Market Session26 Stocks Moving In Wednesday's Pre-Market Session
www.benzinga.com - May 18 at 5:58 PM
Verastem (VSTM) option implied volatility, to present five abstracts, lead product candidate at ASCOVerastem (VSTM) option implied volatility, to present five abstracts, lead product candidate at ASCO
www.streetinsider.com - May 18 at 8:43 AM
Verastem Oncology Announces Pricing of Public Offering of Common StockVerastem Oncology Announces Pricing of Public Offering of Common Stock
www.bizjournals.com - May 17 at 6:37 PM
We Continue To Like VerastemWe Continue To Like Verastem
seekingalpha.com - May 17 at 6:37 PM
Verastem (VSTM) May volatility at 151, to present data on duvelisib and defactinib at ASCOVerastem (VSTM) May volatility at 151, to present data on duvelisib and defactinib at ASCO
www.streetinsider.com - May 17 at 8:24 AM
BRIEF-Verastem Oncology Announces Public Offering Of 7.78 Mln Common Shares Priced At $4.50per ShareBRIEF-Verastem Oncology Announces Public Offering Of 7.78 Mln Common Shares Priced At $4.50per Share
www.reuters.com - May 16 at 5:40 PM
Verastem Oncology to Present Data on Two Lead Drug Candidates at ASCO 2018 Annual MeetingVerastem Oncology to Present Data on Two Lead Drug Candidates at ASCO 2018 Annual Meeting
finance.yahoo.com - May 16 at 5:40 PM
Why Verastem Stock Is Plunging TodayWhy Verastem Stock Is Plunging Today
www.fool.com - May 16 at 2:46 PM
Verastem prices stock offering at $4.50; shares down 15%Verastem prices stock offering at $4.50; shares down 15%
seekingalpha.com - May 16 at 9:53 AM
Benzingas Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma EarningsBenzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings
www.benzinga.com - May 16 at 8:20 AM
BRIEF-Verastem Oncology Announces Public Offering Of Common StockBRIEF-Verastem Oncology Announces Public Offering Of Common Stock
www.reuters.com - May 15 at 5:48 PM
Verastem (VSTM) Commences $35M Common Stock OfferingVerastem (VSTM) Commences $35M Common Stock Offering
www.streetinsider.com - May 15 at 5:48 PM
Verastem Oncology Announces Public Offering of Common StockVerastem Oncology Announces Public Offering of Common Stock
finance.yahoo.com - May 15 at 5:48 PM
Verastem (VSTM) Upgraded at BidaskClubVerastem (VSTM) Upgraded at BidaskClub
www.americanbankingnews.com - May 15 at 12:36 AM
Verastem (VSTM) Forecasted to Post Q2 2018 Earnings of ($0.37) Per ShareVerastem (VSTM) Forecasted to Post Q2 2018 Earnings of ($0.37) Per Share
www.americanbankingnews.com - May 14 at 1:18 AM
Verastem (VSTM) Upgraded to Hold by ValuEngineVerastem (VSTM) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - May 12 at 10:39 AM
Verastem (VSTM) Given a $17.00 Price Target by B. Riley AnalystsVerastem (VSTM) Given a $17.00 Price Target by B. Riley Analysts
www.americanbankingnews.com - May 10 at 5:37 PM
Zacks: Analysts Expect Verastem (VSTM) to Announce -$0.39 Earnings Per ShareZacks: Analysts Expect Verastem (VSTM) to Announce -$0.39 Earnings Per Share
www.americanbankingnews.com - May 7 at 11:08 PM
FY2020 EPS Estimates for Verastem Boosted by Oppenheimer (VSTM)FY2020 EPS Estimates for Verastem Boosted by Oppenheimer (VSTM)
www.americanbankingnews.com - May 7 at 5:17 AM
FY2021 EPS Estimates for Verastem (VSTM) Decreased by Seaport Global SecuritiesFY2021 EPS Estimates for Verastem (VSTM) Decreased by Seaport Global Securities
www.americanbankingnews.com - May 7 at 5:17 AM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - May 4 at 5:32 PM
Verastem (VSTM) Posts  Earnings Results, Misses Estimates By $0.02 EPSVerastem (VSTM) Posts Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - May 4 at 3:32 PM
Verastem: 1Q Earnings SnapshotVerastem: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 8:19 AM
Seaport Global Securities Weighs in on Verastems Q1 2018 Earnings (VSTM)Seaport Global Securities Weighs in on Verastem's Q1 2018 Earnings (VSTM)
www.americanbankingnews.com - May 4 at 5:46 AM
Verastem (VSTM) Given a $17.00 Price Target by Cantor Fitzgerald AnalystsVerastem (VSTM) Given a $17.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 3 at 9:55 PM
BRIEF-Verastem Oncology Reports Q1 Loss Per Share Of $0.41BRIEF-Verastem Oncology Reports Q1 Loss Per Share Of $0.41
www.reuters.com - May 3 at 5:23 PM
Verastem (VSTM) Earns "Buy" Rating from HC WainwrightVerastem (VSTM) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - May 3 at 4:31 PM
Reader Inquiry: Does Verastem Have Further Upside Ahead?Reader Inquiry: Does Verastem Have Further Upside Ahead?
seekingalpha.com - May 3 at 8:17 AM
Verastem Oncology Reports on Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma Opportunity, Landscape and Advancements in Pre-Commercial Initiatives at Analyst and Investor DayVerastem Oncology Reports on Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma Opportunity, Landscape and Advancements in Pre-Commercial Initiatives at Analyst and Investor Day
finance.yahoo.com - May 3 at 8:17 AM
Verastem (VSTM) Lifted to "Sell" at ValuEngineVerastem (VSTM) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - May 2 at 2:02 PM
Verastem (VSTM) Now Covered by Analysts at Seaport Global SecuritiesVerastem (VSTM) Now Covered by Analysts at Seaport Global Securities
www.americanbankingnews.com - May 2 at 11:12 AM
Verastem (VSTM) Scheduled to Post Quarterly Earnings on TuesdayVerastem (VSTM) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 7:12 AM
Verastem (VSTM) Receives Consensus Rating of "Buy" from BrokeragesVerastem (VSTM) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 26 at 5:32 AM
Zacks: Analysts Expect Verastem (VSTM) to Announce -$0.41 Earnings Per ShareZacks: Analysts Expect Verastem (VSTM) to Announce -$0.41 Earnings Per Share
www.americanbankingnews.com - April 20 at 9:24 PM
Cann Reaffirms Buy Rating for Verastem (VSTM)Cann Reaffirms Buy Rating for Verastem (VSTM)
www.americanbankingnews.com - April 16 at 1:54 PM
Verastem (VSTM) in Focus: Stock Moves 8% HigherVerastem (VSTM) in Focus: Stock Moves 8% Higher
finance.yahoo.com - April 13 at 5:31 PM
Are Things Finally Looking Up For Verastem?Are Things Finally Looking Up For Verastem?
seekingalpha.com - April 13 at 8:20 AM
2 Attractive Biotech Stocks Under $102 Attractive Biotech Stocks Under $10
seekingalpha.com - April 12 at 5:38 PM
Verastem: A Solid Player On A Crowded FieldVerastem: A Solid Player On A Crowded Field
seekingalpha.com - April 12 at 5:38 PM
Verastem Forecasted to Post FY2021 Earnings of $2.09 Per Share (VSTM)Verastem Forecasted to Post FY2021 Earnings of $2.09 Per Share (VSTM)
www.americanbankingnews.com - April 11 at 9:19 AM
3 Things In Biotech, April 10: Major Wins For Merck, AbbVie, And Verastem3 Things In Biotech, April 10: Major Wins For Merck, AbbVie, And Verastem
seekingalpha.com - April 11 at 8:32 AM
HC Wainwright Analysts Give Verastem (VSTM) a $7.00 Price TargetHC Wainwright Analysts Give Verastem (VSTM) a $7.00 Price Target
www.americanbankingnews.com - April 10 at 11:38 PM
Verastem (VSTM) Reports Acceptance of NDA for Duvelisib and Grants Priority ReviewVerastem (VSTM) Reports Acceptance of NDA for Duvelisib and Grants Priority Review
www.streetinsider.com - April 9 at 5:20 PM
Cantor Fitzgerald Analysts Give Verastem (VSTM) a $17.00 Price TargetCantor Fitzgerald Analysts Give Verastem (VSTM) a $17.00 Price Target
www.americanbankingnews.com - April 9 at 9:23 AM
Verastem (VSTM) PT Set at $17.00 by Cantor FitzgeraldVerastem (VSTM) PT Set at $17.00 by Cantor Fitzgerald
www.americanbankingnews.com - April 6 at 9:50 PM
-$0.41 Earnings Per Share Expected for Verastem (VSTM) This Quarter-$0.41 Earnings Per Share Expected for Verastem (VSTM) This Quarter
www.americanbankingnews.com - April 3 at 11:33 PM
Verastem (VSTM) Given Average Rating of "Buy" by AnalystsVerastem (VSTM) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 1 at 5:34 AM

SEC Filings

Verastem (NASDAQ:VSTM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Verastem (NASDAQ:VSTM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Verastem (NASDAQ VSTM) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.